About: Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases
Creator	Nicholson, Benjamin Edelmann, Mariola Kessler, Benedikt
source	Medline; PMC
abstract	Recent advances in the development and discovery of pharmacological interventions within the ubiquitin–proteasome system (UPS) have uncovered an enormous potential for possible novel treatments of neurodegenerative disease, cancer, immunological disorder and microbial infection. Interference with proteasome activity, although initially considered unlikely to be exploitable clinically, has already proved to be very effective against haematological malignancies, and more specific derivatives that target subsets of proteasomes are emerging. Recent small-molecule screens have revealed inhibitors against ubiquitin-conjugating and -deconjugating enzymes, many of which have been evaluated for their potential use as therapeutics, either as single agents or in synergy with other drugs. Here, we discuss recent advances in the characterisation of novel UPS modulators (in particular, inhibitors of ubiquitin-conjugating and -deconjugating enzymes) and how they pave the way towards new therapeutic approaches for the treatment of proteotoxic disease, cancer and microbial infection.
has issue date	2011-11-01(xsd:dateTime)
bibo:doi	10.1017/s1462399411002031
bibo:pmid	22088887
has license	cc-by-nc-sa
sha1sum (hex)	c07b523c9bf9af72f5b6ee8b586b13ef619bb3ca
schema:url	https://doi.org/10.1017/s1462399411002031
resource representing a document's title	Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases
has PubMed Central identifier	PMC3219211
has PubMed identifier	22088887
schema:publication	Expert Rev Mol Med
resource representing a document's body	covid:c07b523c9bf9af72f5b6ee8b586b13ef619bb3ca#body_text
is schema:about of	named entity 'DISCUSS' named entity 'INHIBITORS' named entity 'PROTEASOME' named entity 'INTERFERENCE' named entity 'PHARMACOLOGICAL INTERVENTIONS' named entity 'PAVE' named entity 'DISEASE' named entity 'APPROACHES' named entity 'SPECIFIC' named entity 'UNLIKELY' named entity 'WAY' named entity 'therapeutics' named entity 'Here' named entity 'proteasome' named entity 'disorder' named entity 'Pharmacological' named entity 'ubiquitin' named entity 'cancer' named entity 'NEURODEGENERATIVE DISORDERS' named entity 'PHARMACOLOGICAL' named entity 'UBIQUITIN' named entity 'SINGLE' named entity 'NOVEL' named entity 'OFFER' covid:arg/c07b523c9bf9af72f5b6ee8b586b13ef619bb3ca named entity 'CANCER' named entity 'EVALUATED' named entity 'NEW' named entity 'EITHER' named entity 'DEVELOPMENT' named entity 'OTHER DRUGS' named entity 'TREATING' named entity 'INFECTIOUS DISEASES' named entity 'NEW' named entity 'TARGETS' named entity 'SYSTEM' named entity 'SYNERGY' named entity 'ENZYMES' named entity 'THEIR' named entity 'NEURODEGENERATIVE DISEASE' named entity 'MALIGNANCIES' named entity 'TREATMENTS' named entity 'UPS' named entity 'ACTIVITY' named entity 'HERE' named entity 'USE' named entity 'UBIQUITIN' named entity 'MICROBIAL INFECTION' named entity 'UNCOVERED' named entity 'THERAPEUTICS' named entity 'HAVE' named entity 'POSSIBLE' named entity 'MODULATORS' named entity 'CANCER' named entity 'REVEALED' named entity 'PROTEASOMES' named entity 'TREATMENT' named entity 'THERAPEUTIC' named entity 'TARGET' named entity 'RECENT' named entity 'POTENTIAL' named entity 'CONSIDERED' named entity 'INITIALLY' named entity 'DISORDER' named entity 'DISCOVERY' named entity 'IMMUNOLOGICAL' named entity 'EFFECTIVE' named entity 'MOLECULE' named entity 'UBIQUITIN-PROTEASOME SYSTEM' named entity 'HOW' named entity 'SMALL' named entity 'PARTICULAR' named entity 'small-molecule' named entity 'advances' named entity 'uncovered' named entity 'evaluated' named entity 'infection' named entity 'pharmacological' named entity 'ubiquitin'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software